No Data
Optimistic Buy Rating: Strong Phase 2 Results and Regulatory Progress for Verastem's Avutometinib and Defactinib
Verastem Price Target Maintained With a $13.00/Share by RBC Capital
Express News | Cantor Fitzgerald Reiterates Overweight on Verastem
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $7
Truist Financial Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $15
Verastem Stock: Buy Rating Amid Market Overreaction and Promising Commercial Potential